# Release Manifest Verification Report v2.0
**Document Reference:** MAG-VR-v2-11-REL  
**Standard Reference:** IEC 62304:2006+AMD1:2015 §5.8 / ISO 13485:2016 §7.3.7  
**Specification Reference:** [`MAGNIOM-Enterprise Verification, Testing CICD Specification v2.0.md`](file:///home/owner/Downloads/Magniom/public/guides/MAGNIOM-Enterprise%20Verification,%20Testing%20CICD%20Specification%20v2.0.md) (§130–§134)  
**Manifest Reference:** [`docs/verification/v2/v2-verification-baseline-manifest.json`](file:///home/owner/Downloads/Magniom/docs/verification/v2/v2-verification-baseline-manifest.json)  
**Status:** PASS  
**Execution Date:** 2026-09-03  

---

## 1. Executive Summary

This report documents the verification of the **Release Manifest System v2.0**. Under Enterprise Verification Spec §131, every MAGNIOM release produces an immutable, cryptographically signed `MagniomReleaseManifestV2` capturing the exact software commit, database migration version, scientific releases, indication module matrix, and SBOM digests.

Verification confirmed full schema compliance, cryptographic hash reconciliation, and adherence to release signing governance.

---

## 2. Release Manifest Schema Conformance (§131)

The release manifest conforms strictly to the normative interface:
```typescript
interface MagniomReleaseManifestV2 {
  release_id: string;
  application_release: string;
  source_commit: string;
  database_migration_version: string;
  scientific_policy_release_id: UUID;
  evidence_library_release_id: UUID;
  target_engine_release_id: UUID;
  indication_modules: {
    indication_module_release_id: UUID;
    qualification_level: string;
    permitted_modes: string[];
    plugin_digest: SHA256;
  }[];
  measurement_providers: ComponentReleaseRef[];
  reliability_methods: ComponentReleaseRef[];
  sbom_digests: SHA256[];
  test_evidence_digest: SHA256;
  manifest_sha256: SHA256;
  signatures: ReleaseSignature[];
}
```

---

## 3. Clinical Module Matrix Verification (§132)

Verification confirmed that the manifest accurately reflects the multi-module maturity matrix:
- `MDD-2.0.0`: Qualification Level `Q3 / Q8 Baseline`, Permitted Modes: `clinical`, `research`
- `OCD-2.0.0`: Qualification Level `Q3`, Permitted Modes: `validation`, `research`
- `PAIN-NP-2.0.0`: Qualification Level `Q3`, Permitted Modes: `validation`, `research`
- `STROKE-MOTOR-2.0.0`: Qualification Level `Q3`, Permitted Modes: `validation`, `research`
- `STROKE-APHASIA-2.0.0`: Qualification Level `Q3`, Permitted Modes: `research`
- `TBI-2.0.0`: Qualification Level `Q3`, Permitted Modes: `research`
- `PTSD-2.0.0`: Qualification Level `Q3`, Permitted Modes: `research`
- `TINNITUS-2.0.0`: Qualification Level `Q3`, Permitted Modes: `research`

---

## 4. Multi-Signature Release Governance (§14)

Under §14 (No Single-Person Clinical Scientific Release), clinical releases require dual-key cryptographic signing:
1. Enterprise Software Engineering Lead
2. Scientific & Clinical Safety Officer

Both signatures are validated before promotion into staging or production environments.

---

## 5. Conclusion
The Release Manifest v2 system satisfies all supply-chain, traceability, and release governance requirements. Qualified for formal Verification Baseline release.
